Verrica Pharmaceuticals (1NE0) AI Stock Analysis

Company Guidance

Management outlined financial and development guidance and milestones including a nondilutive credit facility of up to $27.5M ($12.5M available immediately, $15M contingent on revenue/growth/operational milestones targeted before end‑2026), no scheduled principal/interest payments until maturity (Dec 2030), priced at SOFR +8% (4.5% floor) with a 1% prepayment fee and a 16% IRR catch‑up, secured seniorly; assuming full availability, cash of $11.2M (June 30, 2026) plus the facility could extend runway into 2028. Q2 2026 operational and financial metrics included total revenue $5.9M (U.S. YCANTH net product revenue $5.1M, up 18.7% QoQ; $0.8M license/collaboration), 19,626 dispensed applicator units (up >28% QoQ and >12% vs Q4 2025), gross product margin ~91.5%, cost of product revenue $0.4M, R&D $6.0M, SG&A $10.3M, a $1.7M net legal settlement expense, GAAP net loss $13.2M ($0.62/sh) and non‑GAAP net loss $10.2M ($0.48/sh). Development guidance: Torii is funding the first $40M (≈90% of current budget) of the global Phase III common‑warts program with overall costs split 50/50, COVE‑3 has dosed first U.S. and Japanese patients while COVE‑2 and long‑term follow‑up COVE‑4 are enrolling, and top‑line data are expected mid‑2027; international expansion includes an Israel distribution deal where Verrica will receive 60% of net selling price plus up to $8.2M in milestones. VP‑315 Phase II highlights noted 14 untreated nontarget BCC lesions across 9 subjects showed a 67% mean size reduction with 3 complete histologic clearances, and the company is preparing for Phase III.